Moderna's story is changing fast, but the stock is already pricing in a lot. See what the Phase 3 cancer result really proves ...
Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are rallying again as investors position ahead of a late-October data drop that could validate the first personalized cancer therapy tested at ...
Following last month's super rally, a growing number of analysts are now calling for caution.
A coveted Presidential Symposium slot at Europe's top oncology congress just sent Moderna shares flying 9%, but the actual ...
Merck and Moderna build a custom mRNA vaccine for each melanoma patient from tumor mutations. The strategy stumbles in cancers lacking enough targets ...
Click here for the report explaining the August 24th YouTube video!Large-scale clinical trial data has been released ...
Moderna (MRNA) stock rose roughly 510% over the year to September 21, 2026, climbing from about $25 to about $173. The S&P ...
But what has the stock done for shareholders lately? How has it done over the past five years? Not so great. It has averaged annual losses over that period -- enough to turn a single $10,000 ...
Phase 3 data for intismeran autogene in the adjuvant treatment of patients with resected stage IIB-IV melanoma selected ...
The biotech giant posted positive trial results of a cancer vaccine, boosting shares at a record-setting pace before investors pulled back.
That came after Moderna and Merck announced their personalized cancer vaccine helped cut the recurrence of melanoma—a form of ...
Moderna built an artificial intelligence that reads a patient’s tumor and decides what that patient’s medicine should be.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results